In silico trials (ISTs) for medical drugs and devices have gained increased popularity as cost-effective alternatives to their clinical counterparts. ISTs promise dramatic reductions in the resources needed for assessing novel technologies and for generating evidence in support of regulatory evaluation for safety and effectiveness. Some have suggested significant cost reductions comparing an all in silico approach versus an equivalent clinical trial with humans. Others have argued for, and reported on, incremental implementation of the in silico methodologies that complement or refine the design of clinical trials based on predictions from the in silico trial outcomes.
Prof Alejandro Frangi - University of Leeds, UK | KU Leuven, Belgium
Dr Aldo Badano - DIDSR/OSEL/CDRH/FDA, USA
Dr Marc Horner - ANSYS, USA
Dr Abhinav Jha - Washington University in St. Louis, USA
Prof Rebecca Shipley – University College London, UK
Dr Ed Margerrison - OSEL/CDRH/FDA, USA
Dr Puja Myles – CPRD/MHRA, UK
Dr Ehsan Abadi – Duke University, USA
Prof Ilse Jonkers - KU Leuven, Belgium
Prof Blanca Rodriguez - University of Oxford, UK
The special issue is still welcoming article proposals from the community, and participants are encouraged to discuss contributions with the guest editors.